Check Claims Before You Publish

Visual summary

Primary evidence & key raw metrics (from the single work)

These quantitative results and downstream analyses are fully available in the preprint and PRIDE deposition (raw files and Supplementary tables) Shutt et al. 2026 metrics & methods

Evidence quality and methodological strengths

• Open, data-rich workflow: enrichment-free global cysteine PTM mapping with LC–MS/MS (FAIMS), crosslinking-MS and full PRIDE deposition (PXD065262) supports independent reanalysis and transparency Shutt et al. 2026 methods & data deposition
• Integrative approach linking proteomics, structural mapping (AlphaFold/AF3), crosslink-MS, and organismal assays (C. elegans, mice, limited human biopsies) increases biological plausibility of regulatory claims Shutt et al. 2026 integrative approach

Limitations, blindspots, and bias risks (explicit)

• Single-author profile with one indexed work to date: low citation count (0) and h-index (0) limit assessment of reproducibility and community uptake (OpenAlex data) OpenAlex author record (Oscar Shutt)
• Preprint status: not peer-reviewed publicly (biorxiv). Strengths of transparency offset by absence of formal peer review and potential revisions; interpret claims cautiously Preprint / bioRxiv status
• Reliance on structure predictions for spatial proximity inferences (AlphaFold/AF3); authors acknowledge that predicted models can misrepresent dynamics and interfaces, so distance-based functional claims are provisional AlphaFold reliance noted
• Limited clinical sample size for human cardiac tissues (7 biopsies total; 6 cardiomyopathy patients and 1 control) reduces generalizability of disease-related statements and increases risk of sampling bias.

Interpretation: how convincing is the science attributed to Oscar Shutt?

The single available paper is methodologically sophisticated and data-rich, and contributes substantive raw datasets and integrative analyses supporting the hypothesis that glutathionylation is widespread and dynamically regulates active-site accessibility and PPIs; however, because Oscar Shutt currently appears as a co-author in a single preprint with no indexed citations, assessing independent author-level impact or reproducible track record is premature OpenAlex bibliometrics & Shutt contribution

Practical takeaways

1. The contribution is scientifically valuable at the dataset and method level — it provides a large, re-usable proteomics resource (PRIDE PXD065262) and multiple testable claims about functional glutathionylation sites Dataset & testable claims
2. From an author-evaluation standpoint, Oscar Shutt shows involvement in high-quality experimental work, but lacks an independent publication/influence record; future peer-reviewed publications and independent citations will be decisive.

Suggested next checks / validation experiments (to strengthen author claims)

• Orthogonal site validation: targeted SRM/PRM or site-directed mutagenesis of key cysteines (actin C259, titin C1249, HSP-12.2 C61) in relevant cell types to confirm modification and functional impact.
• Structural validation: crystallography / cryo-EM or co-immunoprecipitation with site-specific cysteine mutants to confirm predicted interface effects where AlphaFold predictions suggest proximity.
• Clinical replication: larger human cardiac cohorts to test disease-associated glutathionylation increases and network remodeling claims.